Details

Autor(en) / Beteiligte

• Ikegami, Toru
• Soejima, Yuji
• Ohta, Ryuji
• Taketomi, Akinobu
• Yoshizumi, Tomoharu
• Harada, Noboru
• Kayashima, Hiroto
• Maehara, Yoshihiko

Titel

Living donor liver transplantation for hepatitis B associated liver diseases: a 10-year experience in a single center

Ist Teil von

• Hepato-gastroenterology, 2008-07, Vol.55 (85), p.1445

Ort / Verlag

Greece

Erscheinungsjahr

2008

Quelle

MEDLINE

Beschreibungen/Notizen

• Hepatic failure associated with hepatitis B virus (HBV) is one of the main indications for living donor liver transplantation (LDLT). Twenty-nine LDLTs, including liver cirrhosis due to HBV (LC-B) (n = 17) and fulminant hepatitis B (FH-B) (n = 12) were reviewed. Prophylaxis for reinfection was performed with a combination of lamivudine, or hepatitis B immune globulin (HBIG) or adefovir, depending on the viral status. The changes in serological markers, recurrence and survival rate were examined. There were 3 patients with re-emergencies of HBV surface antigen (HBsAg): suspension of HBIG for giving vaccination for HBV (n = 1), HBsAg positive donor (n = 1) and non-compliance for HBIG (n = 1). All patients with YMDD mutants (n = 9), except the case with HBsAg positive donor (n = 1), were successfully protected by the triple therapy of lamivudine, adefovir and HBIG. No graft loss was due to the recurrence of HBV. The basic strategy using a combination of HBIG and antiviral agents gave acceptable long-term outcomes for LDLT for HBV associated liver diseases. The close monitoring of HBV viral status after transplantation is still crucial in managing these patients.